Human bone marrow VCAM-1+ macrophages provide a niche for reactive and neoplastic erythropoiesis by FUJIWARA Hideyo et al.
79Kawasaki Medical Journal 43(2)：79－93，2017　doi：10.11482/KMJ-E43(2)79
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ABSTRACT   Resident bone marrow macrophages provide a microenvironment for 
erythropoiesis, forming erythroblastic islands (EBIs) via adhesion molecules. In this study, 
we examined vascular cell adhesion molecule-1 (VCAM-1) expression in human bone 
marrow specimens using immunohistochemistry. VCAM-1 was strongly expressed in CD169+ 
macrophages in EBIs and weakly in sinusoidal vascular endothelial cells. In reactive 
erythropoiesis, including hemolytic and megaloblastic anemia, the extended cytoplasm of 
VCAM-1+ CD169+ macrophages circumscribed the erythroid cells. The strong affinity between 
VCAM-1+ macrophages and erythroid cells was also observed in polycythemia vera (PV), 
essential thrombocythemia (ET), and chronic myelogenous leukemia (CML). VCAM-1 density 
was significantly higher in PV than in ET and CML (p < 0.001), and correlated with blood 
erythrocyte count in all three neoplasms (p < 0.001). In ET, the VCAM-1 density was higher in 
cases with the JAK2 mutation than with the CALR mutation. In myelodysplastic syndrome with 
erythroid predominance but unclear EBI formation, punctate VCAM-1+ cytoplasmic processes 
of macrophages were seen between erythroblasts, similar to those seen between granulocytic 
precursors in CML, suggesting incomplete contact of VCAM-1+ macrophages with dysplastic 
erythroid cells. These results suggest that VCAM-1+ macrophages create a niche for reactive 
and neoplastic erythropoiesis and may be a therapeutic target in PV.
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〈Regular Article〉
INTRODUCTION
   Bone marrow stroma comprises a variety of 
cell types, including adipocytes, fibroblastic 
reticular cells, endothelial cells, and resident 
macrophages１－４）. These stromal cells provide a 
microenvironment suitable for hematopoiesis by 
secreting various cytokines and by attaching to 
hematopoietic cells via adhesion molecules５－９）. The 
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resident macrophages are located in erythropoietic 
foci, forming erythroblastic islands (EBIs) in 
which erythroblasts are physically close to each 
other but separated by the cytoplasm of the central 
macrophage. Several studies have suggested 
that signals from adhesive interactions with the 
macrophage are important in EBI formation and 
may contribute to the survival and proliferation of 
the erythroid precursors10－14）.
   Vascular cell adhesion molecule-1 (VCAM-1) is a 
transmembrane molecule that mediates the adhesion 
of immune cells to activated endothelial cells and 
macrophages through very late activation antigen 4 
(VLA-4, or α4/β1 integrin) and the integrins α4/
β7, α9/β1, and αD/β2. VLA4 is a ligand of 
VCAM-1 and fibronectin, and it has been shown 
that erythroblasts express it at a high level８）. The 
importance of VLA4/VCAM-1 interactions has been 
demonstrated in the proliferation and survival of 
erythroid progenitors on mouse fetal spleen stromal 
cells10）. In mice, the central macrophage in an EBI 
expresses not only the macrophage pan-marker 
CD16315） and CD169 (known as sialoadhesin or 
Siglec-1)16，17）, but also VCAM-1５，14）. Following 
the  adminis t ra t ion of  granulocyte  colony-
stimulating factor (G-CSF), CD169+ VCAM-1+ 
macrophages were observed to decrease in number 
in bone marrow but not in the spleen; the splenic 
macrophages were able to sustain extramedullary 
erythropoiesis in vivo18，19）.
   Mice treated by injection with l iposome-
encapsulated dichloromethylene diphosphonate 
(Cl2MDP) provide a model for studying the role of 
macrophages and erythropoiesis. The abrogation of 
macrophages by these injections has been shown 
to result in the suppression of mouse splenic 
erythropoiesis stimulated by phlebotomy20）, and 
bone marrow erythropoiesis21）. Other studies 
involving injections with liposome-encapsulated 
Cl2MDP have revealed the supporting activity of 
CD169+ VCAM-1+ stromal macrophages not only 
for reactive erythropoiesis in phenylhydrazine-
treated mice, but also for neoplastic erythropoiesis 
in a JAK2V617F-driven mouse model22，23）. 
   Much less is known about the morphology, 
phenotypes, and distribution of bone marrow 
stromal macrophages and their association with 
hematopoietic cells, clinicopathological parameters, 
and gene mutation status in human hematologic 
diseases. This may be due to the difficulty of 
analyzing EBIs in vitro while retaining their three-
dimensional complex structure. Results so far 
indicate that VCAM-1 is expressed by stromal 
and endothelial cells and plays an important role 
in the adhesion of VLA4+ hematopoietic stem 
cells (HSCs) to sinusoidal endothelial cells during 
their homing into the bone marrow and in the 
mobilization of HSCs５，14，18）. As yet, there has been 
no report evaluating the expression of VCAM-1 by 
bone marrow macrophages in human hematologic 
diseases.
   The aim of this study was to investigate the 
expression of VCAM-1 in human bone marrow 
samples and its association with erythropoiesis 
in myeloproliferative neoplasms. To archive 
this, we first verified the expression of VCAM-1 
in erythropoiesis-associated macrophages by 
immunostaining formalin-fixed paraffin-embedded 
sections of spleen from mice treated by phlebotomy 
and injections of liposomes-encapsulated Cl2MDP. 
Using the same anti-VCAM-1 antibody, we then 
immunostained human bone marrow biopsy samples 
with reactive and neoplastic erythropoiesis, focusing 
on the expression pattern and density of VCAM-
1 in the erythropoiesis-associated macrophages in 
myeloproliferative neoplasms and myelodysplastic 
syndrome.
MATERIALS AND METHODS
Primary antibodies
   The following commercially available antibodies 
were used: the anti-VCAM1 rabbit monoclonal 
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antibody (mAb) (EPR5047, Abcam, Cambridge, 
UK; 1:100 dilution), which also reacts with mouse, 
rat, and human antigens; the anti-CD163 mouse 
mAb (10D6, Leica Biosystems, Newcastle, UK; 
1:200 dilution); the anti-CD169 rabbit mAb (SP213, 
Spring Bioscience, Pleasanton, CA, USA; 1:50 
dilution); the anti-CD146 rabbit mAb (EPR3208, 
Abcam; 1:200 dilution); the anti-CD34 mouse mAb 
(QBend10, Dako, Tokyo, Japan; 1:200 dilution); the 
anti-TP53 mouse mAb (DO7, Dako; 1:50 dilution); 
the rabbit anti-integrin α4 polyclonal antibody 
(MSD, Darmstadt, Germany; 1:500 dilution); the 
rabbit anti-myeloperoxidase polyclonal antibody 
(Dako; 1:500 dilution); the anti-CD71 mouse mAb 
(H68.4, Santa Cruz Biotechnologies, Santa Cruz, 
CA, USA; 1:100 dilution); the anti-CD42b mouse 
mAb (MM2/174, Serotec, Kidlington, UK; 1:200 
dilution); and EB-1 mAb (rat anti-mouse erythrocyte 
band 3 protein mAb), which was produced in our 
laboratory as described previously24）.
Treatment of mice
   Briefly, eight-week-old BALB/c mice weighing 20
－24 g (SLC, Hamamatsu, Japan) were injected i.v. 
with 0.4 ml of phosphate-buffered saline liposome 
suspension or Cl2MDP－liposome suspension20）. 
The mice in the phlebotomy group were bled 
into heparinized capillary tubes from the retro-
orbital sinus (0.5ml) 30 min prior to injection. The 
animals were sacrificed at various times after the 
treatment. The spleens were excised and fixed with 
20% buffered formalin, dehydrated in alcohol, and 
embedded in paraffin. All procedures in this study 
were approved by the Kawasaki Medical School 
Institutional Review Board (number 95-060).
Immunohistochemistry of mouse spleen
   Sections of formalin-fixed paraffin embedded 
tissues 3 μm thick sections were stained with 
the DISCOVERY XT system (Ventana Medical 
Systems, Tucson, AZ, USA) using VCAM-
1 antibodies. For the identification of erythroid 
cells with EB-1 mAb, immunohistochemistry was 
performed with Histofine® Simple Stain Mouse 
MAX-PO (Nichirei Biosciences Inc., Tokyo, Japan).
Human bone marrow samples
   The design of the experiments using human 
bone marrow samples was approved by the Ethics 
Review Board of Kawasaki Medical School and 
Hospital (assigned numbers 1915-1 and 2664). Case 
materials were obtained from Kawasaki Medical 
School Hospital (Kurashiki, Japan). 
   Paraffin-embedded bone marrow samples were 
obtained from a total of 138 patients: 90 biopsy 
cases, and 48 aspirate clot cases. The patients had 
the following diagnoses: hemolytic anemia (n = 10); 
megaloblastic anemia (n = 6); pure red cell aplasia 
(n = 3); myelodysplastic syndrome (MDS; 10 in 
total, 1 MDS-RAEB2, and 9 RDS-RCMD) and 
acute myeloid leukemia (AML; 8 in total, 7 acute 
erythroid leukemia and 1 AML with multilineage 
dysplasia-related changes), of which erythroid 
precursors comprised ≥50% of the bone marrow 
nucleated cells and exhibited impaired formation 
of EBIs, chronic myelogenous leukemia (CML; n 
= 22); polycythemia vera (PV; n = 20); essential 
thrombocythemia (ET; n = 26),　post-polycythemic 
myelofibrosis (n = 5), post-ET myelofibrosis (n = 
3), primary myelofibrosis with overt fibrotic stage 
(n = 4); and, as a control, malignant lymphoma with 
normal hemoglobin values of peripheral blood and 
no bone marrow involvement (n = 21).
   Bone marrow diagnoses  were  confi rmed 
using smears of peripheral blood cell count 
(leukocyte count, erythrocyte count, platelet count, 
hemoglobin value, and hematocrit value), smears 
of peripheral blood and bone marrow, histology, 
immunohistochemistry, flow cytometric analysis, 
chromosome analysis, and gene mutation status 
according to the current World Health Organization 
classification25）. Information on JAK2 and CALR 
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mutation status was extracted from the chart.
Immunohistochemistry of the bone marrow samples
   The bone marrow biopsy tissues were fixed in 
10% buffered formalin overnight or in Bouin’s 
solution for 2 h. Formalin-fixed biopsy tissues were 
decalcified by citrate-buffered formic acid and 
embedded in paraffin. Bouin-fixed biopsy tissues 
were embedded in paraffin without decalcification. 
The bone marrow aspirate clot sections were fixed 
10% buffered formalin overnight or in Bouin’s 
solution for 2 h and then embedded in paraffin. 
The paraffin-embedded sections were cut into 3-
μm thick sections and deparaffinized; the sections 
were then incubated in antigen retrieval CC1 
solution for 60 min at 98℃ and were stained 
using DISCOVERY XT (Ventana) with antibodies 
against CD163 for macrophages, CD169 for 
resident macrophages, CD146 for adventitial 
reticular cells26）, CD34 for endothelial cells and 
HSCs, myeloperoxidase for granulocytes, CD42b 
for megakaryocytes, integrin α4 and CD71 for 
erythroblasts, TP53, and VCAM-1.
Double immunohistochemistry
   Double labeling was performed to determine 
which cell types expressed VCAM-1. Tissue 
sections were stained for CD163, CD169, CD71, 
CD34,  and CD146, and the signals detected 
using diaminobenzidine hydrochloride solution 
and TrueBlueTM Peroxidase Substrate (KPL, 
Gaithersburg, MD, USA).
Image analysis
   A computer-assisted image analysis system 
was used to quantify VCAM-1 density in the 
bone marrow specimens27）. Briefly, bone marrow 
biopsies and aspirate clots were examined by light 
microscopy following immunostaining VCAM-1. 
Four non-overlapping fields per specimen were 
evaluated at a magnification of ×400 using a fully 
automated image analysis system (BZ-X Viewer 
and BZ-X Analyzer; Keyence, Osaka, Japan). The 
VCAM-1 density was expressed as the stained area 
with VCAM-1 as a proportion of hematopoietic 
area (defined as the bone marrow area excluding 
fat). This allowed us to compare the density 
of macrophages regardless of the difference in 
cellularity.
Statistical analysis
   The Mann－Whitney U test  was used for 
comparisons of VCAM-1 density between two 
groups, and the Kruskal－Wallis test was used for 
comparisons among three groups. Correlations 
between VCAM-1 density and peripheral blood 
count were evaluated using Spearman’s rank 
correlation coefficients. P values <0.05 were 
considered significant. The statistical analyses were 
performed using EZR (easy R), available on the 
website of Jichi University (http://www.jichi.ac.jp/
saitama-sct/SaitamaHP.files/ststmed.html)28）, and 
StatMate (StatMate Discovery Software, version 
5.01, ATMS, Tokyo, Japan). 
RESULTS
Immunohistochemical distribution of VCAM-1 in 
the spleens of mice treated with phlebotomy and 
injections of liposome-encapsulated Cl2MDP
   First, we immunostained formalin-fixed paraffin 
embedded sections of mice treated by phlebotomy 
and injections of Cl2MDP encapsulated in 
liposomes using the same anti-VCAM-1 antibody 
as used for the immunostaining of the human bone 
marrow specimens. The kinetics of erythropoiesis 
of splenic red pulp in these mice has been described 
previously19－21）.  In the normal control mice, 
VCAM-1 was expressed in cells that extended 
fine cytoplasmic processes into hematopoietic foci 
and sinus endothelial cells in the red pulp, and 
follicular dendritic cells in the white pulp (Fig. 1a). 
In the spleen of the phlebotomized mouse, large 
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erythropoietic foci formed and each erythroblast 
was individually circumscribed by the dendritic 
cytoplasm of macrophage that were strongly 
positive for VCAM-1 (Fig. 1b). Erythropoietic foci 
were identified using EB-1 monoclonal antibody 
immunostaining. At four days after phlebotomy and 
the injections of liposome-encapsulated Cl2MDP, 
VCAM-1+ macrophages were not seen in the 
splenic red pulp of mice, although VCAM-1 was 
still expressed on reticular and sinus endothelial 
cells in the red pulp. In this point, no erythropoietic 
foci were observed (Fig. 1c). The macrophages had 
almost recovered to their normal level by 10 days 
after treatment and strong VCAM-1 expression on 
the macrophages with cytoplasmic extension was 
observed in the erythropoietic foci (Fig. 1d). These 
findings indicate that VCAM-1+ cells are stromal 
macrophages that are closely associated with 
erythroid precursors. 
Immunohistochemistry of normal human bone 
marrow specimens
   CD163+ macrophages were uniformly distributed 
throughout the hematopoietic cords, frequently 
in association with immature hematopoietic cells 
and megakaryocytes. CD169 was distributed on 
Fig. 1  Immunohistochemical expression of VCAM-1 in mouse spleens. (a) Spleen from a non-treated control mouse. VCAM-1+ 
fine cytoplasmic processes could be identified on macrophages and sinus endothelial cells in the red pulp, and follicular dendritic 
cells in the white pulp. Linear positive staining for VCAM-1 could also be seen under the capsule (C, capsule; W, white pulp; 
R, red pulp). (b) Mouse spleen, one day after phlebotomy and an injection of liposome-encapsulated Cl2MDP. The individual 
erythroblasts were circumscribed by the dendritic cytoplasm of the VCAM-1+ macrophages. (c) Mouse spleen, four days after 
phlebotomy and the injection of liposome-encapsulated Cl2MDP. VCAM-1 expression was limited only sinus endothelial and 
reticular cells. (d) Mouse spleen, 10 days after phlebotomy and the injection of liposome-encapsulated Cl2MDP. VCAM-1 was 
re-expressed in the macrophage associated with erythroblasts.
a b
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macrophages closely associated with erythroid 
cells (Fig. 2a), which expressed CD71 (Fig. 2b) 
and integrin α4. VCAM-1 was strongly expressed 
on the CD169+ cells with dendritic cytoplasmic 
processes, which circumscribed erythroid cells 
(Fig. 2c). VCAM-1 was also faintly expressed on 
CD34+ sinusoidal endothelial cells (Fig. 2d), but not 
on CD146+ adventitial reticular cells. Cytoplasmic 
processes of VCAM-1+ macrophages were partly 
in contact with CD34+ blastic cells, in mainly near 
sinusoid (Fig. 2d).
Reactive erythroid hyperplasia 
   In the specimens from patients with reactive 
erythroid hyperplasia, including hemolytic anemia 
and megaloblastic anemia, the VCAM-1+CD169+ 
macrophages increased in density, extending their 
cytoplasmic processes between erythroid cells 
(Fig. 3a). The VCAM-1 density in the reactive 
erythropoiesis specimens was significantly higher 
than for the control cases (p < 0.001; Fig. 3b). No 
EBIs were observed in pure red cell aplasia, and 
VCAM-1 expression was punctuate between the 
granulocytes (not shown). 
Myelodysplastic syndrome and acute myeloid 
leukemia with ≥ 50% erythroid precursors of 
nucleated cells
   Specimens from 10 patients with MDS, seven 
with acute erythroid leukemia, and one with AML 
Fig. 2  Immunostaining of the human bone marrow control biopsy specimens. (a) CD169 was expressed in the cytoplasmic 
processes of resident macrophages. (b) CD169+ dendritic extensions of the macrophage (brown) appeared to delicately envelope 
CD71+ erythroid cells (blue). (c) The VCAM-1+ cells (brown) were positive for CD169 (blue). (d) The arrowheads indicates the 
sinusoidal endothelial cells that co-expressed VCAM-1 (brown) and CD34 (blue). The black arrows indicate CD34+ blastic cells.
a b
c d
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with multilineage dysplasia-related changes, 
with erythroid precursors comprising ≥50% 
of bone marrow nucleated cells, were stained 
for VCAM-1 and CD169. Erythroid cells were 
markedly increased in these specimens, showing 
clear megaloblastoid changes, a marked increase 
in the number of micromegakaryocytes, and a high 
degree of anemia. Punctate cytoplasmic staining 
of VCAM-1 was observed between dysplastic 
erythroblasts. Double immunostaining for CD71 
and VCAM-1 revealed that this VCAM-1 staining 
pattern represented the impaired formation of 
EBIs (Fig. 3c). CD169 immunostaining showed 
almost same pattern. The VCAM-1 density in these 
MDS cases was significantly higher than for the 
control cases (p < 0.001, Fig. 3b). However, there 
was no differences in VCAM-1 density between 
the reactive erythropoiesis and MDS cases (p = 
0.252, Fig. 3b). In 15 cases, more than 20% of the 
hematopoietic cells were TP53+, indicating the 
TP53 mutation29－33）, but there were no significant 
differences in expression intensity or density of 
Fig. 3  (a) Double immunostaining of VCAM-1 and CD71 in the bone marrow of a patient with reactive erythroid hyperplasia 
(hemolytic anemia). The VCAM-1+ macrophages (brown) were closely associated with CD71+ erythroblasts (blue) and formed 
large erythroblastic islands. (b) Comparison of VCAM-1 expression density in the bone marrow specimens from the control 
samples (n = 21), patients with reactive erythroid hyperplasia (n = 16, 10 with hemolytic anemia and 6 with megaloblastic 
anemia) and patients with myelodysplastic syndrome/acute myeloid leukemia with multilineage dysplasia-related changes (n = 18, 
10 with myelodysplastic syndrome and 8 with acute myeloid leukemia). The reactive erythroid hyperplasia and myelodysplastic 
syndrome/acute myeloid leukemia samples showed significantly higher VCAM-1 densities than the control samples (*p < 
0.001, Mann－Whitney U test). (c) Double immunostaining of VCAM-1 (brown) and CD71 (blue) in the bone marrow of a 
patient with myelodysplastic syndrome, in which erythroid precursors comprised ≥50% of the bone marrow nucleated cells with 
overexpression of TP53. This revealed the impaired formation of erythroblastic islands and punctate cytoplasmic staining of 
VCAM-1 between the erythroblasts.
a
c
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VCAM-1 between these cases and those with less 
than 20% of TP53+ hematopoietic cells. Taken 
together, the findings showed that VCAM-1+ 
macrophages increased in number in MDS but the 
cytoplasmic processes of VCAM-1+ macrophages 
did not circumscribe the dysplastic erythroid 
cells. As a result, tight EBIs were not observed. 
The comparative schema of the immunostaining 
for VCAM-1  staining in cases with reactive 
erythropoiesis or MDS are shown in Fig. 4.
Polycythemia vera
   Bone  mar row samples  f rom 20  pa t i en t s 
with PV were examined. All the cases had the 
JAK2V617F mutation and morphologically showed 
panmyelosis25）. VCAM-1 was strongly expressed 
on macrophages with dendritic cytoplasm closely 
associated with hematopoietic cells, particularly 
erythroblasts (Fig. 5a). The macrophage surrounded 
the entire circumference of erythroblasts, as 
with reactive erythropoiesis, and tight EBIs were 
observed (Fig. 5b). CD169 immunostaining showed 
same staining pattern as VCAM-1 immunostaining.
Essential thrombocythemia
   An examination of the 26  specimens from 
patients with ET showed VCAM-1 was mainly 
expressed on the macrophages in EBIs (Fig. 5c). 
In addition, VCAM-1 expression was observed 
around megakaryocytes (not shown). Image analysis 
revealed significantly greater VCAM-1 expression 
in ET with the JAK2 mutation than in ET with the 
CALR mutation (p = 0.188; Fig. 6a). However, no 
significant correlations were found between the 
Fig. 4  Schema of erythroblastic islands of reactive erythroid hyperplasia and myelodysplastic syndrome with erythroid 
predominance with the overexpression of TP53.
+
+
Reactive erythropoiesis Myelodysplastic syndrome
(with impaired erythroblastic island formation)
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VCAM-1 expression level and leukocyte count, 
platelet count, or erythrocyte count.
Chronic myelogenous leukemia
   All 22  cases of CML showed granulocytic 
hyperplasia. The dendritic immunostaining of 
Fig. 5  Immunostaining of VCAM-1 (a) and double immunostaining of VCAM-1 (brown) and CD71 (blue) (b-e) in bone marrow 
specimens from the patients with myeloproliferative neoplasms. (a,b) In polycythemia vera, the VCAM-1+ macrophages were 
closely associated with CD71+ erythroblasts and formed erythroblastic islands. (c) In essential thrombocythemia, VCAM-1+ 
macrophages were also closely associated with CD71+ erythroblasts and formed erythroblastic islands (JAK2-positive case). (d) 
In chronic myelogenous leukemia (CML), the erythroblastic islands were smaller and less fewer in number. (e) In a CML patient, 
VCAM-1 (brown) was expressed on fine cytoplasmic extensions of macrophages at sites other than erythroblastic islands.
c
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d
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VCAM-1 was mainly observed on macrophages 
in EBIs (Fig. 5d); a punctate staining pattern was 
seen sparsely around granulocytic cells. Double 
immunostaining of VCAM-1 and CD163 or CD169 
confirmed that the cells with the punctate expression 
of VCAM-1 around granulocytes were macrophages 
and not reticular cells (Fig. 5e).
Comparison of the myeloproliferative neoplasms
   Next, we compared VCAM-1 density between 
the PV, ET, and CML specimens. Image analysis 
revealed that VCAM-1 density was significantly 
higher for PV than for ET and CML (chi-squared 
= 35.2, df = 2, p < 0.001, Fig. 6b). A significant 
correlation was observed between VCAM-1 density 
and peripheral blood erythrocyte count (correlation 
coefficient = 0.554, p < 0.001, Fig. 6c), but not 
between VCAM-1 density and the leukocyte or 
platelet count. 
Myelofibrosis
   In specimens from the five cases of post-
polycythemic myelofibrosis, CD163+ macrophages 
exhibited spindle morphology in fibrotic areas, as 
previously observed using immunohistochemistry 
with the anti-CD68 mAb (PG-M1) (Fig. 7a)27）. 
Fig. 6  (a) The VCAM-1 expression density in the bone marrow biopsy specimens of essential thrombocythemia (ET) patients 
with the JAK2 mutation (n = 9) was significantly higher than that for patients with the CALR mutation (n = 9) (*p < 0.05, Mann
－Whitney U test). (b) The VCAM-1 expression density in the bone marrow biopsy specimens of patients with polycythemia vera 
(PV; n = 20) was higher than that for patients with ET (n = 26) or chronic myelogenous leukemia (CML; n = 22) (**chi-squared 
= 35.2, df = 2, p < 0.001, Kruskal－Wallis test). (c) The VCAM-1 expression density in the bone marrow specimens of patients 
with myeloproliferative disorders (PV, ET, and CML) correlated significantly with the erythrocyte count (correlation coefficient = 
0.554, p < 0.001, Spearman’s correlation test).
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Fig. 7  Immunostaining of the bone marrow of patients with post-polycythemia vera myelofibrosis. (a) CD163+ macrophages 
elongated cytoplasmic processes along the array of collagen fibers (b,c). The CD169+ (b) and VCAM-1+ (c) cells showed a similar 
staining pattern.
CD169+ macrophages were reduced in number and 
were often associated with residual erythropoietic 
foci (Fig. 7b), but the macrophages exhibited 
spindle morphology in fibrotic areas, as seen 
with the CD163 immunostaining. VCAM-1 was 
also expressed on the spindle cells, not only on 
macrophages and endothelial cells, but also on 
fibroblastic stromal cells (Fig. 7c). The same 
tendency was seen in specimens from three cases 
of post-ET myelofibrosis and four cases of primary 
myelofibrosis.
DISCUSSION
   The result of this study clearly showed, using 
the same antibody for VCAM-1 as used in the 
immunohistochemical study of the mice injected 
with liposome-encapsulated Cl2MDP, that the 
main human bone marrow VCAM-1+ cells are a 
subpopulation of CD163+ macrophages and that they 
express CD169. We also confirmed the association 
between VCAM-1+ macrophages and erythroblasts 
in reactive erythropoiesis induced by phlebotomy 
in mice, and hemolytic and megaloblastic anemia 
in humans. In addition, image analysis confirmed 
an increase in VCAM-1  density in reactive 
erythropoiesis in human bone marrow.
   So-called tumor-associated macrophages have 
been shown to form a tumor microenvironment 
and affect tumor progression and metastasis34，35）; 
however, there have been few studies of bone 
marrow macrophages in hematopoietic neoplasms. 
We found that VCAM-1+ macrophages tended 
a b
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to be more closely associated not only with 
reactive erythropoiesis but also with neoplastic 
erythropoiesis, than with granulopoiesis. The 
macrophages were mainly associated with erythroid 
cells, with their cytoplasmic circumscribing each 
erythroid cells. VCAM-1 density was higher in 
specimens from cases of PV than from cases of 
ET and CML. Furthermore, VCAM-1 expression 
density showed a strong correlation with peripheral 
blood cell count in PV, ET, and CML. These 
observations suggest that the erythropoiesis in 
PV remained under the control of VCAM-1+ 
macrophages. 
   The following can be inferred about the role 
of macrophages in PV from previous studies of 
mice. First, VCAM-1+ macrophages could help 
the proliferation of erythroblasts, and/or inhibit 
their apoptosis. Second, VCAM-1+ macrophages 
efficiently perform phagocytosis of the pyrenocytes 
(nuclei surrounded by plasma membranes) excluded 
from erythroblasts36）. One possible mechanism 
underlying the significant increase in VCAM-1+ 
macrophages in erythropoietin-dependent reactive 
erythropoiesis and JAK2-mutated PV and ET is that 
JAK2/STAT5 signaling was activated simultaneously 
in both erythroblasts and macrophages. The 
regulatory mechanism for VCAM-1 expression 
in the macrophages that provide a niche for 
erythropoiesis warrants investigation. 
   A comparison of the cases with JAK2  and 
CALR mutations in ET showed a significantly 
higher density of VCAM-1+ macrophages in those 
with the JAK2. VCAM-1+CD169+ macrophages 
were associated not only with erythropoietin-
dependent reactive erythropoiesis, but also with 
neoplastic erythropoiesis caused by the mutation, 
suggesting that the kinetics of the VCAM-1+CD169+ 
macrophage subpopulation was regulated by some 
unknown factor involved in both reactive and 
neoplastic erythropoiesis.
   A recent study suggested that the loss of bone 
marrow VCAM-1 expression in myelofibrosis 
caused a bone marrow homing defect of CD34+ 
HSCs, although the cell type that expressed VCAM-1 
was unclear37）. In the present immunohistochemical 
study of myelofibrosis, VCAM-1+ macrophages 
changed to a spindle morphology aligning to 
fiber’s arrangement, regardless of whether the 
myelofibrosis was post-PV, post-ET, or primary. 
This morphological change may be associated with 
insufficient functioning of the macrophages and 
could result in peripheral erythroblastosis, probably 
through the loss of the tight adhesive interaction 
between macrophages and erythroblasts. 
   It has previously been shown that the number 
of CD68+ bone marrow macrophages increased in 
MDS33，38，39）. This increase may contribute to the 
elimination of apoptotic cells. In the present study, 
VCAM-1+ macrophages were present in MDS 
with a dysplastic erythroid predominance, but each 
dysplastic erythroid cell was not well enveloped 
by the cytoplasm of the VCAM-1+ macrophages. 
Another recent study reported that the impaired 
formation of EBIs of dysplastic erythroblasts have 
reduced expression of α4 integrin on dysplastic 
erythroblasts40）. As a result, there may be no tight 
EBI formation, as is shown schematically in Fig. 4. 
It has also been shown that impaired formation of 
EBIs is associated with erythroid feature and poor 
prognosis in a significant proportion of patients 
with myelodysplastic syndromes41）. Insufficient 
envelopment of erythroblasts by VCAM-1+ 
macrophages may not only lead to a decrease in 
anti-apoptotic signaling by adhesion molecules, 
including VLA4/VCAM-1, but may also facilitate 
erythroblast－erythroblast interaction and induce 
apoptosis by Fas－Fas ligand signaling, because 
high expression of Fas and Fas ligands was observed 
in MDS42，43）.
   In summary, the present results showed that 
CD169+VCAM-1+ macrophages were closely 
associated with reactive and neoplastic erythropoiesis 
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in human diseases. The macrophages may promote 
late erythroid maturation, particularly in PV, which 
is characterized by extremely high erythrocytosis 
and is associated with the constitutively active 
JAK2V617F mutation. Thus, modulation of the 
macrophages by targeting VCAM-1 may be a new 
strategy to treat PV.
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